Tue, April 19, 2011
Mon, April 18, 2011
[ Mon, Apr 18th 2011 ] - Market Wire
00 a.m. ET
Sun, April 17, 2011
Fri, April 15, 2011
Thu, April 14, 2011
Wed, April 13, 2011
Tue, April 12, 2011
Mon, April 11, 2011
Sun, April 10, 2011
Sat, April 9, 2011
Fri, April 8, 2011
Thu, April 7, 2011
[ Thu, Apr 07th 2011 ] - Market Wire
Volunteering Does a Body Good
Wed, April 6, 2011
Tue, April 5, 2011
Mon, April 4, 2011
Sun, April 3, 2011
Sat, April 2, 2011
Fri, April 1, 2011
Thu, March 31, 2011
Wed, March 30, 2011

Anacor Pharmaceuticals to Present at the Fifth Annual aResistance is Futile: the Challenge of Antibacterial Drug Developmenta C


//health-fitness.news-articles.net/content/2011/ .. llenge-of-antibacterial-drug-developmenta-c.html
Published in Health and Fitness on Monday, April 11th 2011 at 5:40 GMT by Market Wire   Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that Dickon Alley, Ph.D., Senior Research Leader, will be presenting at the Fifth Annual aResistance is Futile: the Challenge of Antibacterial Drug Developmenta Conference hosted by Drug Discovery Chemistry in San Diego on Tuesday, April 12, 2011 at 4:30 p.m. PT. The subject of Dr. Alleya™s presentation is aTackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials.a Slides from Dr. Alleya™s presentation will be available following the presentation at [ www.anacor.com ] under News & Events.

"Tackling Microbial Resistance: Novel Targets Accessed by Boron Antibacterials."

AboutAnacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds that are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK a052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed toGlaxoSmithKlineunder the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit[ http://www.anacor.com ].


Publication Contributing Sources